Evidence map›Paper›PMID 42465974›Full record

ArticlePeerJ2026

Prognostic biomarkers for enhanced risk stratification in extraskeletal myxoid chondrosarcoma: a retrospective cohort study.

Amphun Chaiboonchoe, Jantappapa Chanthercrob, Romgase Sakamula, Thanaphon Likhityungyuen, Sorranart Muangsomboon, Jomjit Chantharasamee, Francis Lee, Krittawat Suwanpukdee, Pannin Thanapipatsiri, Rapin Phimolsarnti and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amphun ChaiboonchoeSiriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Jantappapa ChanthercrobSiriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Romgase SakamulaSiriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Thanaphon LikhityungyuenSiriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Sorranart MuangsomboonDepartment of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Jomjit ChantharasameeDivision of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Francis LeeDepartment of Orthopaedics and Rehabilitation, Yale University, Connecticut, United States of America.
Krittawat SuwanpukdeeDepartment of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Pannin ThanapipatsiriDepartment of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Rapin PhimolsarntiDepartment of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Apichat AsavamongkolkulDepartment of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Somponnat SampattavanichSiriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Chandhanarat ChandhanayingyongDepartment of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft-tissue sarcoma driven by the Methods: We performed whole-transcriptome targeted RNA sequencing (TempO-Seq) on archival formalin-fixed paraffin-embedded (FFPE) tumor specimens from 12 molecularly confirmed EMC cases. To explore potential biological markers, the cohort was stratified into good-prognosis ( Results: We identified 550 differentially expressed genes and derived a three-gene prognostic candidate ( Conclusions: This integrated transcriptomic and spatial immune characterization identifies

Indexed as

Biomarkers, TumorChondrosarcomaNeoplasms, Connective and Soft TissueAdultAgedFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentTranscriptomeBiomarkers, TumorExtraskeletal myxoid chondrosarcomaLASSO–CoxregressionPrognostic biomarkersTempO-SeqTumor immune microenvironment

Identifiers

PMID42465974
PMCPMC13374579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.